For patients with EGFR-mutant lung cancer experienced better response to EGFR-TKI or chemotherapy as compared to those with EGFR wild-type one if the patients suffered from disease recurrence into advanced stage (31–34), this may partly explain the discrepancy in results between our research and prior studies. The gene discussed is EGFR; the disease is lung cancer.